JA
Therapeutic Areas
Invivyd Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VYD222 (Invymab) | Prevention of COVID-19 | Phase 3 |
| Next-Generation COVID-19 mAb | COVID-19 | Preclinical/Discovery |
| Influenza mAb Programs | Influenza | Discovery/Preclinical |
Leadership Team at Invivyd
MM
Michael Mina
Chief Medical Officer
RA
Robert Allen
Chief Scientific Officer
WD
William Duke
Chief Financial Officer
RG
Rachael Gerlach
Senior Vice President of Regulatory Affairs
JG
Julie Green
Chief Human Resources Officer
TL
Timothy Lee
Chief Commercial Officer